Remove FDA Remove Sterile Compounds Remove Vaccines
article thumbnail

Out of Shortage, Into Controversy: The Fight Over GLP-1 Compounding

Pharmacy Times

Rumore, PharmD, Esq, MS, LLM, FAPhA Key Takeaways The removal of tirzepatide and semaglutide from the FDA's shortage list impacts 503A compounders, requiring adherence to complex legal and regulatory frameworks. SHOW MORE GLP-1 compounding faces legal challenges, evolving FDA rules, and heightened enforcement risks.

article thumbnail

Preventing fungal contamination in pharmaceuticals

European Pharmaceutical Review

In a review on fungal-contaminated compounded pharmaceuticals and medical devices, researchers have described how the contamination of these products can be due to breaches in sterile compounding procedures. Ahmed et al. Ahmed et al. One case of drug contamination from 2021 was highlighted in the paper.